Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35335   clinical trials with a EudraCT protocol, of which   5785   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-000181-34
    Sponsor's Protocol Code Number:OBI-1-301
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-08-07
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2011-000181-34
    A.3Full title of the trial
    Efficacy and Satefy of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
    Efficacia e sicurezza del Fattore VIII Ricombinante porcino privo del dominio B (OBI-1) nel trattamento dell'Emofilia A acquisita dovuta a auto-anticorpi inibitori anti-fattore VIII.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of a new factor VIII replacement for patients with acquired hemophilia A
    Studio di una nuova sostituzione del fattore VIII per pazienti affetti da emofilia A acquisita
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberOBI-1-301
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01178294
    A.5.4Other Identifiers
    Name:NANumber:NA
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorINSPIRATION BIOPHARMACEUTICALS
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInspiration Biopharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationVoisin Consulting
    B.5.2Functional name of contact pointClinical Trial Unit
    B.5.3 Address:
    B.5.3.1Street Address3 rue des Longs Pres
    B.5.3.2Town/ cityBoulogne-Billancourt
    B.5.3.3Post code92100
    B.5.3.4CountryFrance
    B.5.4Telephone numberND
    B.5.5Fax numberND
    B.5.6E-mailclinicaltrialinformation@voisinconsulting.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/10/784
    D.3 Description of the IMP
    D.3.1Product nameOBI-1
    D.3.2Product code OBI-1
    D.3.4Pharmaceutical form Powder and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeOBI-1
    D.3.9.3Other descriptive namerecombinant porcine coagulation factor VIII (B domain deleted)
    D.3.10 Strength
    D.3.10.1Concentration unit U unit(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number350 to 650
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acquired Haemophilia A
    Emofilia A acquisita
    E.1.1.1Medical condition in easily understood language
    Blood disorder characterized by bleeding episodes, spontaneous or in response to minimal trauma that usually occurs in the elderly
    Malattia del sangue caratterizzata da episodi emorragici spontanei o causati da banali traumi, che si manifesta in genere nei soggetti anziani
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10053761
    E.1.2Term Acquired hemophilia with anti FVIII, XI, or XIII
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of OBI-1 for the treatment of serious bleeding episodes in subjects with acquired hemophilia with autoimmune inhibitors to human factor VIII.
    Valutare l’efficacia di OBI 1 nel trattamento di episodi emorragici seri in soggetti con emofilia acquisita con auto-anticorpi inibitori anti-fattore VIII umano.
    E.2.2Secondary objectives of the trial
    1.Proportion of serious bleeding episodes controlled with OBI-1. 2.Efficacy of OBI-1 at designated time points after the initiation of therapy. 3.Frequency, total dose, and total number of infusions of OBI-1 required to control all serious bleeding episodes. 4.Correlation between response to anti-OBI-1 therapy at specified assessment time points and eventual control of serious bleeding episodes. 5.Correlation between the preinfusion anti-OBI-1 inhibitor titer, the total dose of OBI-1, the outcome at 24 hours and the eventual control of the bleeding episode. 6.Anti-OBI-1 inhibitor level preinfusion, at specified time points during treatment, and at 90 days post final infusion. 7.Safety of OBI-1. 8.Drug exposure using complete or sparse sampling design and population PK approach when therapy with OBI-1 is successful.
    1.Proporzione di episodi emorragici seri controllati tramite terapia con OBI-1.2.Efficacia di OBI-1 in time point determinati,dall’inizio della terapia.3.Frequenza,dosaggio totale e numero totale di infusioni di OBI 1 necessari per controllare tutti gli episodi emorragici seri.4.Correlazione tra risposta alla terapia con OBI-1in specifici time-point di valutazione e eventuale controllo degli episodi emorragici seri.5.Correlazioni tra la preinfusione di titolo inibitore anti-OBI-1,il dosaggio totale di OBI-1,l’esito a 24 ore e infine il controllo di episodi emorragici.6.Preinfusione di inibitore anti-OBI-1 in time-point specifici durante il trattamento e a 90 giorni dall’ultima infusione.7.Sicurezza di OBI-1.8.Esposizione a farmaci tramite un disegno di campionamento completo o sparso su popolazione PK quando la terapia con OBI-1 ha avuto risultati positivi.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Males or females ≥18 years of age. 2.Written informed consent from subject or subject’s legal representative. 3.Subjects with acquired hemophilia with autoimmune inhibitory antibodies to human factor VIII with a clinical diagnosis established by the following criteria: a)Prolonged activated partial thromboplastin time (aPTT) b)Prothrombin time (PT) ≤ULN + 2 seconds and platelet count within normal range c)Abnormal aPTT mixing study (patient normal control 1:1) consistent with a factor VIII inhibitor d)Reduced factor VIII activity level (below 10%) 4.Has a serious bleeding episode, as documented by the investigator. 5.Be willing and able to follow all instructions and attend all study visits. 6.Subjects taking antithrombotics (such as clopidogrel, heparin or heparin analogue) may be included provided three half lives of the agent have elapsed since the last dose of the agent. 7.Life expectancy of at least 90 days prior to the onset of the bleeding episode. 8.Subjects of reproductive age will be required to use acceptable methods of birth control and, if female, undergo pregnancy testing as part of the screening process.
    1.Maschi o femmine ≥18 anni d’età. 2.Consenso informato scritto del soggetto o del suo rappresentante legale. 3.Soggetti con emofilia acquisita con auto-anticorpi inibitori anti fattore VIII umano e diagnosi clinica stabilita secondo i criteri seguenti: a)Prolungamento del tempo di tromboplastina parziale attivata (aPTT) b)Tempo di protrombina (PT)≤ULN + 2 secondi e conteggio piastrine nella norma c)Studio misto aPTT anomalo (paziente-normale controllo 1:1) coerente con inibitori di fattore VIII d)Livello di attività fattore VIII ridotto (sotto il 10%). 4.Serio episodio emorragico documentato dal ricercatore. 5.Disposto e in grado di seguire tutte le istruzioni e di sottoporsi a tutte le visite previste dallo studio. 6.Possono essere inclusi soggetti che assumono antitrombotici (come clopidogrel, eparina o analoghi delle eparine) purché siano trascorse tre emivite dall’ultimo dosaggio. 7.Aspettativa di vita, prima dell’insorgere dell’episodio emorragico, di almeno 90 giorni. 8.I soggetti in età riproduttiva devono usare metodi di contraccezione adeguati. Le donne devono sottoporsi ad un test di gravidanza all‟interno del processo di screening.
    E.4Principal exclusion criteria
    1.Hemodynamically unstable after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy. 2.Has an established reason for bleeding that is not correctable. 3.Bleeding episode assessed likely to resolve on its own if left untreated. 4.Anti-OBI-1 inhibitor that exceeds 20 BU (prospectively or retrospectively). 5.Subsequent bleeding episode at the site of the initial qualifying bleeding episode within two weeks following the final OBI-1 dose for the initial qualifying bleeding episode, or subsequent bleeding episode at a different site than the initial qualifying bleeding episode within 1 week following the final OBI-1 dose for the initial qualifying bleeding episode will not be considered “new” qualifying bleeding episodes. 6.Prior history of bleeding disorder other than acquired hemophilia. 7.Known major sensitivity (anaphylactoid reactions) to therapeutic products of porcine or hamster origin; examples include therapeutics of porcine origin (e.g. previously marketed porcine factor VIII, Hyate-C) and recombinant therapeutics prepared from hamster cells (e.g. Humira, Advate and Enbrel). 8.Use of hemophilia medication: rFVIIa within 3 hours prior to OBI-1 administration or aPCC treatment within 6 hours prior to OBI-1 administration. 9.Participation in any other clinical study within 30 days of the first OBI-1 treatment. 10.Anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of OBI-1, or whose safety or efficacy may be affected by OBI-1. 11.Is currently pregnant or planning to become pregnant or father a child during the study. 12.Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject’s safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study. 13.Inability or unwillingness to comply with the study design, protocol protocol requirements, or the follow-up procedures.
    1.Emodinamicamente instabile dopo trasfusione sanguigna, ripristino dei fluidi e pressoterapia farmacologica o per ripristino della volemia. 2.Motivi constatati di sanguinamento non correggibile. 3.Episodio emorragico valutato suscettibile di risolversi senza trattamento. 4.Inibitore anti-OBI-1 superiore a 20 BU (prospettivamente e retrospettivamente). 5.Gli episodio emorragici nel sito dell’episodio emorragico iniziale qualificante entro due settimane dal dosaggio finale di OBI-1 per l’episodio emorragico iniziale qualificante, o gli episodi emorragici in siti diversi dal sito dell’episodio emorragico iniziale qualificante entro 1 settimana dal dosaggio finale di OBI-1 per l’episodio emorragico iniziale qualificante, non saranno considerati episodi emorragici qualificanti “nuovi”. 6.Storia pregressa di disturbi emorragici diversi dall‟emofilia acquisita. 7.Nota intolleranza (reazioni anafilattiche) nei confronti di prodotti terapeutici di origine porcina o derivati dal criceto; ad esempio terapie di origine porcina (es. fattore VIII porcino precedentemente in commercio, Hyate-C) e ricombinanti terapeutici preparati con cellule di criceto (es. Humira, Advate and Enbrel). 8.Uso di farmaci per l‟emofilia: rFVIIa entro le 3 precedenti la somministrazione di OBI-1 o trattamento con aPCC entro le 6 ore precedenti la somministrazione di OBI-1. 9.Partecipazione in altro studio clinico entro 30 giorni dal primo trattamento con OBI-1. 10.Esigenza anticipata di trattamento o dispositivo durante lo studio che potrebbe interferire con la valutazione della sicurezza o dell'efficacia di OBI-1, o la cui sicurezza o efficacia potrebbero essere alterate dall'OBI-1. 11.Gravidanza in corso o gravidanza o paternità previste durante lo studio. 12.Esami anomali alla base, altre condizioni mediche o risultati di laboratorio che, secondo il ricercatore, potrebbero mettere a rischio la sicurezza del soggetto o diminuire le possibilità di ottenere i dati soddisfacenti necessari per raggiungere gli obiettivi dello studio. 13.Incapacità o mancanza di volontà di attenersi al disegno dello studio, ai requisiti di protocollo, o alle procedure di controllo.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the proportion of serious bleeding episodes responsive to OBI-1 therapy at 24 hours after the initiation of treatment. Response to OBI-1 therapy will be based on assessment of effectiveness and factor VIII blood levels.
    L’endpoint primario di efficacia è la percentuale di episodi di emorragie gravi rispondenti alla terapia OBI-1 a 24 ore dall’inizio del trattamento. La risposta alla terapia OBI-1 si baserà sulla valutazione dell’efficacia e sui livelli di fattore VIII del sangue.
    E.5.1.1Timepoint(s) of evaluation of this end point
    At 24hours
    Ad 24 h
    E.5.2Secondary end point(s)
    Secondary Efficacy Endpoints:
    1.The overall proportion of serious bleeding episodes successfully controlled with OBI-1 therapy, as assessed by the investigator.
    2.The proportion of bleeding episodes responsive to OBI-1 therapy at designated assessment time points after the initiation of therapy, as assessed by the investigator.
    3.Frequency, total dose, and total number of infusions of OBI-1 required to successfully control qualifying bleeding episodes.
    4.Correlation between response to OBI-1 therapy at specified time points and eventual control of serious bleeding episodes.
    5.Correlation between the pre-infusion anti-OBI-1 antibody titers, the total dose of OBI-1, the outcome at 24 hours and the eventual control of the bleeding episode.
    6.Drug exposure will be determined by means of population PK analysis for the sparse (bleeding state data) and compartmental analysis for the complete (non-bleeding) data. At least the following PK parameters will be estimated: Cl, Vd, area under the concentration-time curve (AUC) and Cmax/Dose.
    Safety endpoints:
    1.TEAEs and serious adverse events (SAEs) throughout the study.
    2.Biochemistry, hematology, urinalyses and vital signs.
    3.Anti-human factor VIII antibody titer.
    4.Anti-OBI-1 antibody titer.
    5.Anti-host cell protein (BHK) antibody titer.
    Endpoints secondari di efficacia:
    1.La percentuale complessiva di episodi emorragici gravi controllati con successo con la terapia OBI-1, così come verificato dall’investigatore.
    2.La percentuale di episodi emorragici rispondenti alla terapia OBI-1 nei time point di valutazione stabiliti dopo l’inizio della terapia, così come verificato dall’investigatore.
    3.Frequenza, dosaggio totale e numero totale di infusioni di OBI-1 richieste per controllare con successo gli episodi emorragici qualificanti.
    4.Correlazione tra risposta alla terapia OBI-1 nei time point specificati e controllo finale degli episodi emorragici gravi.
    5.Correlazione tra i titoli anticorpali anti-OBI-1 della pre-infusione, il dosaggio totale di OBI-1, il risultato a 24 h e il controllo finale dell’episodio emorragico.
    6.L’esposizione al farmaco sarà determinato tramite la popolazione Analisi PK per i dati sporadici (dati sullo stato dell’emorragia) e analisi compartimentale per i dati completi (non-emorragici). Saranno valutati almeno i seguenti parametri PK: Cl, Vd, area al di sotto della curva concentrazione-tempo (AUC) e Cmax/Dosaggio.
    Endpoints di sicurezza:
    1.Eventi avversi che emergono in corso di trattamento (TEAEs) ed eventi avversi gravi (SAEs) per tutta la durata dello studio.
    2.Biochimica, ematologia, analisi delle urine e segni vitali.
    3.Titolo anticorpale anti-fattore VIII umano.
    4.Titolo anticorpale anti-OBI-1.
    5.Titolo anticorpale dell’anti-proteina della cellula ospite (BHK).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy:
    1-5.Each dose or q8h to 24h;24h;each dose or q12h from 24- 120h;each dose or q24h thereafter until last OBI-1 dose or withdrawal.
    6.Screening; 10-20min;each dose or q8h to 24h;24h;each dose or q12h from 24-120h;each dose or q24h thereafter until last OBI-1 dose or withdrawal;optional:last OBI-1 dose.
    Safety:
    1.Ongoing basis throughout study including follow-up.
    2.Vital signs:screening;10-20min after end of first dose; each dose or q8h up to 24h;24h;each dose or q12h from 24h-120h;each dose or q24h thereafter until last OBI-1 dose or withdrawal;follow-up. Analyses:screening;at each dose or q8h to 24h;24h;follow-up.
    3-4.Screening;q5 days during treatment;follow-up.
    5.Screening;follow-up.
    Efficacia:
    1)-5)Ogni dose o ogni (oo) 8ha24h;24h;ogni dose oo 12hda24-120h; ogni dose oo 24h dopo termine prima dose fino ultima dose di OBI-1 o ritiro.
    6)Screening; 10-20 min; ogni dose oo 8ha24h; 24h; ogni dose oo 12hda24-120h; ogni dose oo 24h dopo termine prima dose fino ultima dose di OBI-1 dose o ritiro; facoltativo: ultima dose di OBI-1.
    Sicurezza:
    1.Su base continua per tutta la durata dello studio, compreso il follow-up (FU).
    2.Segni vitali:screening; 10-20 min dopo la fine della prima dose; ogni dose oo 8hfino a24h; 24h; ogni dose oo 12h da24h-120h; ogni dose oo 24h dopo termine prima dose fino ultima dose di OBI-1 o ritiro; FU.
    Analisi:screening; ad ogni dose oo 8ha24h; 24h; FU.
    3-4.Screening;ogni 5 giorni durante trattamento;FU.
    5.Screening,FU.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA18
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    India
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months18
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 4
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 24
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    As the bleeding episodes may be life threatening bleeding episodes, the patient may not be in a position to consent. A legal representative may do so on the patient's behalf.
    Poiché gli episodi emorragici possono essere mortali, il paziente può non essere in grado di dare il suo consenso. Un rappresentante legale può dare il consenso per conto del paziente.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 18
    F.4.2.2In the whole clinical trial 28
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    It is expected that the need for treatment will be completed, i.e. the bleed will have been managed. Most subjects will then be immunosuppressed and in the majority the acquired antibody will be suppressed and there will be no need for future treatment.
    Si prevede che il trattamento necessario sia terminato, ossia che l’emorragia sia tenuta sotto controllo. La maggior parte dei soggetti sarà dunque trattata con immunosoppressori e in gran parte di loro l’anticorpo acquisito sarà soppresso e non vi sarà pertanto bisogno di futuri trattamenti.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-05-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-04-17
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2014-01-28
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA